ZIMMER BIOMET HOLDINGS, INC. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Zimmer Biomet reported Q2 2026 net sales of $2.177B (+4.8% reported, +4.0% organic constant currency) and diluted EPS of $1.03 (+33.8%), with adjusted diluted EPS of $2.07 (flat YoY). The company raised full-year 2026 revenue guidance from 2.5-4.5% to 3.9-4.9% reported growth and adjusted diluted EPS guidance from $8.40-$8.55 to $8.47-$8.59. Management also announced plans to repurchase up to $1 billion in common stock during 2026. Six-month operating cash flow was $807.2M with $554.1M in free cash flow.
Why this rating
Raised guidance modest but positive; 4.0% organic growth and $1B buyback solid for $18B company; not transformational given modest revenue lift and flat adjusted EPS YoY.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.